Explore
Urological Cancer 2021
0 Ungluers have
Faved this Work
Login to Fave
Cancer of the urological sphere is a disease continuously increasing in numbers in the statistics of tumor malignancies in Western countries. Although this fact is mainly due to the contemporary increase of life expectancy of the people in these geographic areas, many other factors do contribute as well to this growth. Urological cancer is a complex and varied disease of different organs and mainly affects the male population. In fact, kidney, prostate, and bladder cancer are regularly included in the top-ten list of the most frequent neoplasms in males in most statistics. The female population, however, has also increasingly found itself affected by renal and bladder cancer in the last decade. Considering these altogether, urological cancer is a problem of major concern in developed societies. This Topic Issue of Cancers intends to shed some light into the complexity of this field and will consider all useful and appropriate contributions that scientists and clinicians may provide to improve urological cancer knowledge for patients’ benefit. The precise identification of the molecular routes involved, the diagnostic pathological criteria in the grey zones, the dilemma of T1G3 management, and the possible treatment options between superficial, nonmuscle-invasive and muscle-invasive diseases will be particularly welcomed in this Issue.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 58 times via unglue.it ebook links.
- 58 - pdf (CC BY) at Unglue.it.
Keywords
- 177Lu-PSMA
- abiraterone
- ablation margins
- advanced urothelial carcinoma
- AHNAK2
- Autopsy
- Bacillus Calmette–Guérin (BCG)
- biomarker
- biomarkers
- Biopsy
- Bladder cancer
- bladder cancer cell lines
- bladder carcinoma
- Cancer
- cell migration
- Chemistry
- comparative effectiveness
- comparative oncology
- ctDNA
- Decision making
- Diagnosis
- divergent differentiation
- docetaxel
- dog
- enzalutamide
- epiplakin
- epithelial–mesenchymal transition
- fluorescence confocal microscopy
- focal therapy
- frail patients
- Frailty
- FTY-720
- Game theory
- genomic analysis
- genomic signatures
- glutaminase
- Hounsfield units
- image-guided
- immune checkpoint inhibitor
- immune checkpoint inhibitors
- immunohistochemistry
- Immunotherapy
- in situ methods
- Inflammation
- inflammatory indices
- latent cancer
- Liquid Biopsy
- Machine learning
- Magnetic Resonance Imaging
- Mathematics & science
- mCRPC
- metastasectomy
- metastasis
- metastatic prostate cancer
- microenvironment
- molecular subtypes
- Mortality
- n/a
- novel hormonal therapies
- OIP5
- oncological outcomes
- papillary renal cell carcinoma
- PD-1
- PD-L1
- PLK1
- positron-emission tomography
- postoperative complications
- preclinical studies
- prediction model
- preneoplastic lesion
- prognosis
- prognostic
- prognostic factor
- prognostic index
- Prostate
- prostate biopsy
- prostate cancer
- prostatic atrophy
- prostatic neoplasms
- PSA
- PSMA-RLT
- psoas muscle
- radical cystectomy
- radiosensitisation
- Radiotherapy
- real-world treatment pattern
- Reference, information & interdisciplinary subjects
- renal cell carcinoma
- Research & information: general
- screening trial
- sphingosine 1-phosphate receptor 1
- stereotactic body radiotherapy
- Survival
- Therapy
- tripod
- tumor ecology
- tumor thrombus
- tumorigenesis
- tumour mutational board
- Ultrasonography
- urinary bladder neoplasms
- urine
- urothelial carcinoma
- variant morphology
Links
DOI: 10.3390/books978-3-0365-3049-9Editions